ATM and ovarian cancer: In their latest update, the National Comprehensive Cancer Network (NCCN) guidelines, although suggesting a strong association between high-risk ATM mutations (c.7271T > G) and both breast and ovarian cancer, do not recommend any risk-reducing surgery [24].